|
|
|
|
|
|
|
23.06.26 - 19:06
|
How Eli Lilly′s CEO Plans to Defeat Pharma′s Boom-Bust Cycle (Bloomberg)
|
|
|
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege.
Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare.
Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
23.06.26 - 06:00
|
How AI integration into real-world tasks enhances healthcare and education (SCMP)
|
|
|
The growing use of artificial intelligence (AI) in our daily lives has become a constant topic of worldwide conversation. Its most proclaimed everyday benefits of the technology include boosting efficiency, productivity and decision-making, but developing and deploying it is a much more complicated matter.
The next phase of its adoption will be defined not by access to the technology, but by the ability to translate AI capabilities into real-world outcomes. In education and healthcare,......
|
|
|
|
|
22.06.26 - 15:31
|
„Wäre keineswegs ein Abbau der Gesundheitsqualität, im Gegenteil“ (Die Welt)
|
|
|
WELT-Chefökonomin Dorothea Siems unterstützt die Reformvorschläge von Gesundheitsministerin Warken und fordert insbesondere weniger Krankenhäuser, um das Personal an größeren Standorten effizienter zu bündeln und so dem Personalmangel entgegenzuwirken. „Hätte also noch einen Nebeneffekt.“...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|